Zacks Research Has Positive Estimate for BIO FY2024 Earnings

Bio-Rad Laboratories, Inc. (NYSE:BIO) – Research analysts at Zacks Research increased their FY2024 EPS estimates for shares of Bio-Rad Laboratories in a research report issued to clients and investors on Wednesday, November 20th. Zacks Research analyst R. Department now forecasts that the medical research company will post earnings per share of $10.18 for the year, up from their prior forecast of $9.46. The consensus estimate for Bio-Rad Laboratories’ current full-year earnings is $9.93 per share. Zacks Research also issued estimates for Bio-Rad Laboratories’ Q4 2025 earnings at $3.28 EPS, FY2025 earnings at $11.44 EPS, Q1 2026 earnings at $3.15 EPS and Q2 2026 earnings at $3.08 EPS.

Bio-Rad Laboratories (NYSE:BIO) last posted its quarterly earnings data on Wednesday, October 30th. The medical research company reported $2.01 EPS for the quarter, topping the consensus estimate of $1.16 by $0.85. Bio-Rad Laboratories had a negative net margin of 30.18% and a positive return on equity of 3.74%. The business had revenue of $649.70 million during the quarter, compared to the consensus estimate of $628.18 million. During the same period in the previous year, the firm posted $2.33 earnings per share. The business’s revenue for the quarter was up 2.8% compared to the same quarter last year.

BIO has been the subject of several other reports. StockNews.com raised Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a report on Friday, November 1st. Citigroup raised their price target on shares of Bio-Rad Laboratories from $400.00 to $450.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $340.00 price objective on the stock. Finally, Royal Bank of Canada raised their target price on shares of Bio-Rad Laboratories from $446.00 to $469.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $391.80.

Bio-Rad Laboratories Stock Performance

Shares of BIO opened at $332.91 on Monday. The company has a debt-to-equity ratio of 0.16, a quick ratio of 4.52 and a current ratio of 6.14. The stock has a 50-day moving average of $340.52 and a two-hundred day moving average of $316.27. The stock has a market cap of $9.32 billion, a P/E ratio of -12.18 and a beta of 0.93. Bio-Rad Laboratories has a one year low of $262.12 and a one year high of $387.99.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. UMB Bank n.a. raised its position in Bio-Rad Laboratories by 140.6% during the third quarter. UMB Bank n.a. now owns 77 shares of the medical research company’s stock worth $26,000 after acquiring an additional 45 shares during the period. Capital Advisors Ltd. LLC increased its stake in shares of Bio-Rad Laboratories by 193.8% during the second quarter. Capital Advisors Ltd. LLC now owns 94 shares of the medical research company’s stock worth $26,000 after purchasing an additional 62 shares in the last quarter. Gladius Capital Management LP acquired a new position in shares of Bio-Rad Laboratories during the 3rd quarter worth about $32,000. EntryPoint Capital LLC purchased a new position in Bio-Rad Laboratories in the 1st quarter valued at about $51,000. Finally, Point72 Hong Kong Ltd acquired a new stake in Bio-Rad Laboratories in the 3rd quarter worth about $55,000. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Insiders Place Their Bets

In other news, COO Andrew J. Last sold 3,000 shares of the stock in a transaction dated Friday, September 6th. The shares were sold at an average price of $329.94, for a total transaction of $989,820.00. Following the sale, the chief operating officer now directly owns 7,559 shares of the company’s stock, valued at $2,494,016.46. This represents a 28.41 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP James Barry sold 623 shares of the firm’s stock in a transaction dated Wednesday, September 4th. The shares were sold at an average price of $330.49, for a total value of $205,895.27. Following the sale, the executive vice president now owns 147 shares in the company, valued at $48,582.03. This trade represents a 80.91 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 17.06% of the company’s stock.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.